Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme analog presented as a 250 mg lyophilized powder for solution for injection for intravenous use. It treats acute intermittent porphyria, hereditary coproporphyria and variegate porphyria in patients experiencing acute attacks.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Normosang is used to manage acute porphyria attacks by restoring heme levels and suppressing toxic precursor accumulation.

Acute intermittent porphyria: reduces neurotoxic ALA and PBG buildup, relieving abdominal and neurological symptoms. Hereditary coproporphyria: decreases porphyrin precursor accumulation, helping control acute neurovisceral episodes. Variegate porphyria: limits accumulation of porphyrin intermediates, mitigating severe attack manifestations.

Human Hemin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the infusion site. - Phlebitis: inflammation of the vein used for administration. - Fever: transient elevation of body temperature. - Nausea: occasional feeling of sickness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hemolysis: rapid destruction of red blood cells, especially in patients with G6PD deficiency. - Acute renal failure: sudden loss of kidney function observed in rare cases.

When using Normosang, several precautions should be observed to ensure safety and efficacy.

- Indication verification: confirm diagnosis of an acute porphyria attack before administration. - G6PD deficiency screening: avoid use in patients with known glucose‑6‑phosphate dehydrogenase deficiency. - Monitoring of vital signs: observe blood pressure, temperature and heart rate during infusion. - Iron overload assessment: evaluate iron status, as repeated dosing may increase iron stores. - Drug compatibility: ensure compatibility with IV fluids and avoid mixing with calcium‑containing solutions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Porphyrin‑inducing drugs: avoid concurrent use of barbiturates, sulfonamides, or antiepileptics that may exacerbate porphyria. - Iron‑containing preparations: concurrent high‑dose IV iron may increase risk of iron overload.

Moderate Interactions (Monitor Closely): - Anticoagulants: hemin may affect coagulation parameters; monitor INR or aPTT. - Antifungal agents (e.g., azoles): may alter hemin metabolism; observe clinical response. - Vitamin D analogues: potential additive effect on calcium metabolism; check serum calcium.